Apotea (APOTEA) - Net Assets
Based on the latest financial reports, Apotea (APOTEA) has net assets worth Skr940.60 Million SEK (≈ $101.22 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.22 Billion ≈ $238.99 Million USD) and total liabilities (Skr1.28 Billion ≈ $137.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check APOTEA cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr940.60 Million |
| % of Total Assets | 42.35% |
| Annual Growth Rate | 34.29% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.22 |
Apotea - Net Assets Trend (2022–2025)
This chart illustrates how Apotea's net assets have evolved over time, based on quarterly financial data. Also explore Apotea asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Apotea (2022–2025)
The table below shows the annual net assets of Apotea from 2022 to 2025. For live valuation and market cap data, see APOTEA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr859.90 Million ≈ $92.54 Million |
+35.20% |
| 2024-12-31 | Skr636.00 Million ≈ $68.44 Million |
+49.65% |
| 2023-12-31 | Skr425.00 Million ≈ $45.74 Million |
+19.72% |
| 2022-12-31 | Skr355.00 Million ≈ $38.20 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Apotea's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 166.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr832.60 Million | 98.65% |
| Other Components | Skr11.40 Million | 1.35% |
| Total Equity | Skr844.00 Million | 100.00% |
Apotea Competitors by Market Cap
The table below lists competitors of Apotea ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hebei Huijin Electromechanical Co Ltd
SHE:300368
|
$863.02 Million |
|
WUS Printed Circuit Co Ltd
TW:2316
|
$863.15 Million |
|
Celebi Hava Servisi AS
IS:CLEBI
|
$863.19 Million |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS
|
$863.22 Million |
|
Bain Capital Specialty Finance Inc
NYSE:BCSF
|
$862.75 Million |
|
Shanghai Baosteel Packaging
SHG:601968
|
$862.49 Million |
|
Neo Performance Materials Inc
TO:NEO
|
$862.44 Million |
|
Double Bond Chemical Ind Co Ltd
TW:4764
|
$862.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apotea's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 615,200,000 to 844,000,000, a change of 228,800,000 (37.2%).
- Net income of 228,700,000 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr228.70 Million | +27.1% |
| Other Changes | Skr100.00K | +0.01% |
| Total Change | Skr- | 37.19% |
Book Value vs Market Value Analysis
This analysis compares Apotea's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 24.48x to 9.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | Skr3.15 | Skr77.05 | x |
| 2023-12-31 | Skr3.88 | Skr77.05 | x |
| 2024-12-31 | Skr5.91 | Skr77.05 | x |
| 2025-12-31 | Skr8.11 | Skr77.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apotea utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.17%
- • Asset Turnover: 3.64x
- • Equity Multiplier: 2.35x
- Recent ROE (27.10%) is above the historical average (22.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 6.08% | 0.41% | 3.90x | 3.82x | Skr-12.85 Million |
| 2023 | 21.55% | 1.60% | 4.08x | 3.31x | Skr46.63 Million |
| 2024 | 34.93% | 3.29% | 4.02x | 2.65x | Skr153.38 Million |
| 2025 | 27.10% | 3.17% | 3.64x | 2.35x | Skr144.30 Million |
Industry Comparison
This section compares Apotea's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
No peer company data available for comparison.
About Apotea
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and dr… Read more